While the data may support pushing back the timeline for routine mammograms from age 40 to 50 for women, Arthur Caplan questions the decision in his most recent MSNBC column saying that "there is every reason to doubt that the numbers they compiled will be sufficient to overturn a medical... (read the rest)
posted November 19, 2009
As a woman and a supporter of research of all kinds, I still have a hard time swallowing this request: "You are healthy. You feel great. Can you help us out by participating in a research study where we will biopsy your breast and take out healthy tissue for our... (read the rest)
posted April 17, 2009
Last week in his MSNBC column, Art Caplan asks whether breast cancer genetic tests are worth the price or whether biotech companies are cashing in on women's cancer fears. Below is the full text of the column: Breast cancer gene tests -- not worth the price? Biotechnology firms hope to... (read the rest)
posted October 13, 2008
On Thursday, 23andMe announced their latest initiative aimed at bringing together the largest cohort of women with breast cancer "to build an infrastructure, based on genetics, that will accelerate consumer-based research of the disease." The women who opt for 23andMe's genetic testing services can opt-in for other kinds of surveys... (read the rest)
posted October 3, 2008
If you use an RSS reader, you can subscribe to a feed of all future entries from blog.bioethics.net tagged 'breast cancer'. [What is this?]
The American Journal of Bioethics is published by Taylor & Francis Health Sciences
The Blog is Funded in part by a grant from The Greenwall Foundation
(#5-39182 (8), "Bioethics Education Network"; PI: Glenn McGee)